Alzheimers Pipeline Drugs Review, Alzheimers Disease Drug Market & Forecast - Global Analysis @ http://www.researchmoz.us/alzheimers-pipeline-drugs-review-alzheimers-disease-drug-market-and-forecast-global-analysis-report.html

1. Alzheimers Pipeline Drugs Review, Alzheimers Disease Drug Market & Forecast - Global Analysis
Alzheimer’s disease drug market is on the curvature stage. Since 2003, there is not any single
“magic bullet” launched in the market to prevent or cure it. However, all current marketed
products are going to be generic in the next 3-4 years. There are high unmet medical needs. The current unmet
needs represent a huge opportunity for pharmaceutical companies which are developing targeted novel
therapies. If successful, they will be in a position to command premium prices and tap the existing
opportunity. Lot of drugs has failed in Phase III stage thus putting a greater impact on Alzheimer’s
disease drug market.
From the year 2009 Alzheimer’s disease drug market is declining and it is expected to fall till 2016.
But with the expected launch of some Alzheimer’s drugs from the year 2017 onwards,
Alzheimer’s disease drug market is expected to revive in the coming years. However due to absence of
exact potential drugs there will always remain a huge Unmet Alzheimer’s Drug Market. For the year
2018 Alzheimer’s Disease Drug Market will be just 10% of Unmet Alzheimer’s Disease Drug
Market.
Renub Research study titled “Alzheimer’s Pipeline Drugs Review, Alzheimer’s Disease
Drug Market & Forecast – Global Analysis” provides a comprehensive assessment of the
fast-evolving, high-growth Global Alzheimer’s Disease Market. This 110 page report with 29 Figures
and 11 Tables studies the Global Alzheimer’s Disease Drug Market.
Present & Pipeline Drugs Studied in this Report
Namenda Ebixa Axura Aricept Nootropil Exelon Memary Solanezumab LuAe58054 This report contains 10
chapters.
(Chapter 1): Executive Summary
(Chapter 2): This Chapter is divided into 2 parts
A. Alzheimer’s Disease Drug Market & Forecast data available from 2003 to 2018
B. Unmet Alzheimer’s Disease Drug Market & Forecast (Market Potential) data available from 2010
to 2018. (Unmet market is the potential market which could have been achieved if right drug have been
introduced in the market)
(Chapter 3): This chapter talks about drugs which has failed while in Clinical trials
(Chapter 4): This chapter provides Market Share of Alzheimer’s Disease Drug from 2003 to 2018. All
the 9 Alzheimer’s drug mentioned above have been covered in this chapter.
(Chapter 5): This chapter talks about Alzheimer’s Drugs performance. All important drugs mentioned
above past, present & future market data available from 2003 to 2018.
(Chapter 6): Pipeline drugs (Solanezumab, LuAE58054, Gantenerumab, Crenezumab, TRx0237 (LMTX),
MK-8931, ABT-126, AZD-1446) have been analyzed in this chapter. All drugs have been analyzed from 5
view points:
A. Clinical Development Stage B. Pipeline Drug Sales Performance C. Recent Clinical Development D.
Different Companies Deal E. Investment
(Chapter 7): This chapter speaks of Alzheimer’s Drugs Company deals in four areas
A. Strategic Alliances in Alzheimer’s Disease Drug Market B. Licensing Agreement in
Alzheimer’s Disease Drug Market C. Collaboration Deal in Alzheimer’s Disease Drug Market
Alzheimers Pipeline Drugs Review, Alzheimers Disease Drug Market & Forecast - Global Analysis

2. D. Merger & Acquisition in Alzheimer’s Disease Drug Market
(Chapter 8): This chapter studies Funding in Alzheimer’s Disease Drugs Research. We have covered 5
institutes which provides fund for the research.
A. National Institute of Health B. Alzheimer's Association C. Cure Alzheimer’s Fund D.
Alzheimer’s Drug Discovery Foundation E. BrightFocus Foundation [formerly American Health
Assistance Foundation (AHAF)]
(Chapter 9): This chapter studies Growth Factors Driving the Alzheimer’s Disease Drug Market.
(Chapter 10): This chapter studies Challenges/Hindrances faced by Alzheimer’s Disease Drug
Market.
Data Sources
This report is built using data and information sourced from proprietary databases, primary and secondary
research and in-house analysis by Renub Research team of industry experts.
Primary sources include industry surveys and telephone interviews with industry experts.
Secondary sources information and data has been collected from various printable and non-printable sources
like search engines, News websites, Government Websites, Trade Journals, White papers, Government
Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and
access to more than 500 paid databases.
table Of Content
1. Executive Summary
2. Worldwide – Alzheimer’s Disease Drug Market Analysis
2.1 Alzheimer’s Disease Drug Market & Forecast
2.2 Unmet Alzheimer’s Disease Drug Market & Forecast (market Potential)
3. Failed Alzheimer’s Drugs
3.1 Dismal Results But Still Trying Again
4. Worldwide – Alzheimer’s Disease Drug Market Share & Forecast
5. Worldwide – Alzheimer’s Drug Brands Market Performance
5.1 Exelon (rivastigmine) – Past, Present & Future Market
5.2 Aricept (donepezil) – Past, Present & Future Market
5.3 Memantine (namenda, Ebixa, Axura, Memary) Past, Present & Future Market
5.3.1 Namenda (memantine) – Past, Present & Future Market
5.3.2 Ebixa (memantine) – Past, Present & Future Market
5.3.3 Axura (memantine) – Past, Present & Future Market
Alzheimers Pipeline Drugs Review, Alzheimers Disease Drug Market & Forecast - Global Analysis

3. 5.3.4 Memary (memantine) – Past, Present & Future Market
5.4 Nootropil (piracetam) – Past, Present & Future Market
6. Pipeline Drugs Analysis In Alzheimer’s Disease Market
6.1 Solanezumab (ly2062430) – Eli Lilly
6.1.1 Clinical Development Stage
6.1.1.1 Phase – Ii
6.1.1.2 Phase – Iii
6.1.2 Solanezumab Drug Sales (2017 – 2020)
6.1.3 Recent Clinical Development
6.2 Luae58054 – Lundbeck
6.2.1 Clinical Development Stage
6.2.1.1 Phase – Ii
6.2.2 Luae58054 Drug Sales (2017 – 2018)
6.2.3 Deal On Luae58054
6.3 Gantenerumab – Roche
6.3.1 Clinical Development Stage
6.3.1.1 Phase – I
6.3.1.2 Phase – Ii & Iii
6.3.1.3 Phase – Iii
6.3.2 Investment In Gantenerumab Drug
6.4 Crenezumab – Genentech
6.4.1 Clinical Development Stage
6.4.1.1 Phase – Ii
6.4.2 Investment In Crenezumab Drug
6.5 Trx0237 (lmtx) – Taurx Therapeutics Ltd.
6.5.1 Clinical Development Stage
6.5.1.1 Phase – Ii
6.5.1.2 Phase – Iii
6.5.2 Investment In Trx0237 (lmtx) Drug
6.6 Mk-8931 – Merck
6.6.1 Clinical Development Stage
6.6.1.1 Phase – Ii/iii
6.7 Abt-126 – Abbvie
6.7.1 Clinical Development Stage
6.7.1.1 Phase – I
6.7.1.2 Phase – Ii
6.8 Azd-1446 – Targacept/astrazeneca
6.8.1 Clinical Development Stage
6.8.1.1 Phase – I
6.8.2 Recent Development
Alzheimers Pipeline Drugs Review, Alzheimers Disease Drug Market & Forecast - Global Analysis

4. 7. M&a, Licensing Agreement, Strategic Alliances & Collaboration Deals In Alzheimer’s Disease
Drug Market
7.1 Strategic Alliances In Alzheimer’s Disease Drug Market
7.2 Licensing Agreement In Alzheimer’s Disease Drug Market
7.3 Collaboration Deal In Alzheimer’s Disease Drug Market
7.4 Merger & Acquisition In Alzheimer’s Disease Drug Market
8. Funding In Alzheimer’s Disease Drugs Research
8.1 National Institute Of Health
8.2 Alzheimer's Association
8.3 Cure Alzheimer’s Fund
8.4 Alzheimer’s Drug Discovery Foundation
8.5 Brightfocus Foundation [formerly American Health Assistance Foundation (ahaf)]
9. Key Drivers Of Growth In Global Alzheimer’s Disease Drug Market
9.1 Aging Population
9.1.1 Global Ageing Indicators
9.1.2 Population Aged 60 Or Over: World And Development Regions, 1950 – 2050
9.1.3 Worldwide - Distribution Of Population Aged 60 Years Or Over By Broad Age Group, 1950 –
2050
9.2 Unmet Medical Needs
9.3 The Launches Of New Drugs Solanezumab, Luae58054, Gantenerumab & Trx0237 Will Boost The
Alzheimer’s Market Through 2018
9.4 Future Drugs For Disease Modification In Alzheimer’s Disease
10. Key Challenges In The Global Alzheimer’s Disease Drug Market
10.1 Lack Of Validated Targets & Lack Of Animal Models
10.2 Barriers In The Design And Implementation Of Clinical Trials
10.3 Barriers In Academia & Regulatory Issues
10.4 Alzheimer’s Drug Failure: Insinuation For Future R&d In Neuroscience
10.5 Costly Alzheimer’s Drug Development Dissuade Drug Companies
10.6 Research Setbacks And Stepping Stones
ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research
reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our
huge collection of market research reports. We provide our services to all sizes of organizations and across all
industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as
publishers and will assist you in making an informed decision by giving you unbiased and deep insights on
which reports will satisfy your needs at the best price.
Alzheimers Pipeline Drugs Review, Alzheimers Disease Drug Market & Forecast - Global Analysis

5. Contact:
M/s Sheela,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
Alzheimers Pipeline Drugs Review, Alzheimers Disease Drug Market & Forecast - Global Analysis